# EDGAR Filing Document

**Accession Number:** 0001781983
**File Stem:** 0001104659-26-028509
**Filing Date:** 2026-3
**Character Count:** 20342
**Document Hash:** 6f285946d4eb685784431e799fa2ec95
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-028509.hdr.sgml**: 20260316

**ACCESSION NUMBER**: 0001104659-26-028509

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 14

**FILED AS OF DATE**: 20260316

**DATE AS OF CHANGE**: 20260316

**EFFECTIVENESS DATE**: 20260316

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Aprea Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001781983
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-294351
- **FILM NUMBER:** 26757257

**BUSINESS ADDRESS:**
- **STREET 1:** 3805 OLD EASTON ROAD
- **CITY:** DOYLESTOWN
- **STATE:** PA
- **ZIP:** 18902
- **BUSINESS PHONE:** 215-948-4119

**MAIL ADDRESS:**
- **STREET 1:** 3805 OLD EASTON ROAD
- **CITY:** DOYLESTOWN
- **STATE:** PA
- **ZIP:** 18902

As filed with the Securities and Exchange Commission on March 16, 2026

Registration No. 333-_________

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM S-8**

**REGISTRATION STATEMENT**

**UNDER**

**THE SECURITIES ACT OF 1933**

**APREA THERAPEUTICS, INC.**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Delaware** | **84-2246769** |
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |

---

---

| | |
|:---|:---|
| **3805 Old Easton Road**<br> **Doylestown, PA**  | **18902** |
| (Address of Principal Executive Offices) | (Zip Code) |

---

**Aprea Therapeutics, Inc. 2019 Equity Incentive Plan**

(Full title of the plan)

**Oren Gilad, Ph.D.**

**President and Chief Executive Officer**

**3805 Old Easton Road**

**Doylestown, PA 18902**

**215-948-4119**

(Name, address and telephone number, including area code, of agent for service)

***Copies t*** **o:**

**Fahd M.T. Riaz, Esq.**

**DLA Piper LLP (US)**

**One Liberty Place**

**1650 Market Street, Suite 5000**

**Philadelphia, PA 19103-7300**

**215-948-4119** 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large Accelerated filer ◻ Accelerated filer ◻ <br> Non-accelerated filer ⌧ Smaller reporting company ⌧ <br> Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ◻

**Part II**

**Information Required In The Registration Statement**

This Registration Statement relates to the registration of an additional 327,701 shares (the "***Shares***") of Aprea Therapeutics, Inc. (the "***Registrant***") Common Stock, par value $0.001 per share. The Shares are securities of the same class and relate to the same employee benefit plan, the Aprea Therapeutics, Inc. 2019 Equity Incentive Plan (in the form attached hereto as Exhibit 99.1) (the "***2019 Plan***"), as those registered pursuant to the Registrant's registration statements on Form S-8, previously filed with the Securities and Exchange Commission on [November 18, 2019 (Registration No. 333-234765)](https://www.sec.gov/Archives/edgar/data/1781983/000110465919065133/a19-23106_1s8.htm), [November 12, 2020 (Registration No. 333-250043)](https://www.sec.gov/Archives/edgar/data/1781983/000110465920124493/tm2035651-1_s8.htm), [November 9, 2021 (Registration No. 333-260884)](https://www.sec.gov/Archives/edgar/data/1781983/000110465921135795/tm2132154d1_s8.htm), [December 15, 2022 (Registration No. 333-268816)](https://www.sec.gov/Archives/edgar/data/1781983/000110465922127391/tm2232644d1_s8.htm), [November 9, 2023 (Registration No. 333-275440)](https://www.sec.gov/Archives/edgar/data/1781983/000110465923116308/tm2329846d1_s8.htm), [August 21, 2024 (Registration No. 333-281683)](https://www.sec.gov/Archives/edgar/data/1781983/000110465924091607/tm2421014d1_s8.htm), and <u>[December 8, 2025 (333-291998)](https://www.sec.gov/Archives/edgar/data/1781983/000110465925119074/tm2532817d1_s8.htm)</u>.

In accordance with General Instruction E of Form S-8, the contents of the Registrant's registration statements filed with the Securities and Exchange Commission on [November 18, 2019 (Registration No. 333-234765)](https://www.sec.gov/Archives/edgar/data/1781983/000110465919065133/a19-23106_1s8.htm), [November 12, 2020 (Registration No. 333-250043)](https://www.sec.gov/Archives/edgar/data/1781983/000110465920124493/tm2035651-1_s8.htm), [November 9, 2021 (Registration No. 333-260884)](https://www.sec.gov/Archives/edgar/data/1781983/000110465921135795/tm2132154d1_s8.htm), [December 15, 2022 (Registration No. 333-268816)](https://www.sec.gov/Archives/edgar/data/1781983/000110465922127391/tm2232644d1_s8.htm), [November 9, 2023 (Registration No. 333-275440)](https://www.sec.gov/Archives/edgar/data/1781983/000110465923116308/tm2329846d1_s8.htm), [August 21, 2024 (Registration No. 333-281683)](https://www.sec.gov/Archives/edgar/data/1781983/000110465924091607/tm2421014d1_s8.htm), and [<u>December 8, 2025 (333-291998)</u>](https://www.sec.gov/Archives/edgar/data/1781983/000110465925119074/tm2532817d1_s8.htm) are incorporated herein by reference (solely to the extent the contents of such registration statements relate to the 2019 Plan) and the information required by Part II is omitted, except as supplemented by the information set forth below.

**Item 8** **Exhibits.**

---

| | |
|:---|:---|
| **Exhibit <br> No.** | **Description** |
| [4.1](https://www.sec.gov/Archives/edgar/data/1781983/000110465919053259/a19-12476_12ex3d1.htm#Exhibit3_1_102107) | [Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K, filed with the Commission on October 7, 2019)](https://www.sec.gov/Archives/edgar/data/1781983/000110465919053259/a19-12476_12ex3d1.htm#Exhibit3_1_102107) |
| [4.2](https://www.sec.gov/Archives/edgar/data/1781983/000110465923018997/tm236225d1_ex3-1.htm) | [Certificate of Amendment to Amended and Restated Certificate of Incorporation of Aprea Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on February 13, 2023)](https://www.sec.gov/Archives/edgar/data/1781983/000110465923018997/tm236225d1_ex3-1.htm) |
| [4.3](https://www.sec.gov/Archives/edgar/data/1781983/000110465922061599/tm2215660d3_ex3-1.htm) | [Certificate of Designation of Series A Non-Voting Series A Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on May 17, 2022)](https://www.sec.gov/Archives/edgar/data/1781983/000110465922061599/tm2215660d3_ex3-1.htm) |
| [4.4](https://www.sec.gov/Archives/edgar/data/1781983/000155837020013179/apre-20200930ex31ca25522.htm) | [Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, filed with the Commission on November 6, 2020)](https://www.sec.gov/Archives/edgar/data/1781983/000155837020013179/apre-20200930ex31ca25522.htm) |
| [5.1\*](tm268514d1_ex5-1.htm) | [Opinion of DLA Piper LLP (US).](tm268514d1_ex5-1.htm) |
| [23.1\*](tm268514d1_ex23-1.htm) | [Consent of EisnerAmper LLP](tm268514d1_ex23-1.htm) |
| [23.2\*](tm268514d1_ex5-1.htm) | [Consent of DLA Piper LLP (US) (included in Exhibit 5.1).](tm268514d1_ex5-1.htm) |
| [24](#a_002) | [Power of Attorney (contained on the signature page hereto).](#a_002) |
| [99.1](https://www.sec.gov/Archives/edgar/data/1781983/000104746919005499/a2239779zex-10_1.htm) | [Aprea Therapeutics, Inc. 2019 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Registrant's Registration Statement (Form S-1/A), filed with the Commission on September 27, 2019)](https://www.sec.gov/Archives/edgar/data/1781983/000104746919005499/a2239779zex-10_1.htm) |
| [107\*](tm268514d1_ex-filingfees.htm) | [Filing Fee Table](tm268514d1_ex-filingfees.htm) |

---

\* Filed herewith

**SIGNATURE**

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement with respect to the Aprea Therapeutics, Inc. 2019 Equity Incentive Plan, to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Doylestown, Commonwealth of Pennsylvania, on March 16, 2026.

---

| | |
|:---|:---|
| **Aprea Therapeutics, Inc.** | **Aprea Therapeutics, Inc.** |
| By: | /s/ Oren Gilad |
| Name: | Oren Gilad, Ph.D. |
| Title: | President and Chief Executive Officer |

---

**POWER OF ATTORNEY**

The officers and directors of Aprea Therapeutics, Inc. whose signatures appear below hereby constitute and appoint Oren Gilad and John Hamill, and each of them, their true and lawful attorneys and agents, with full power of substitution, each with power to act alone, to sign and execute on behalf of the undersigned this Registration Statement on Form S-8 with respect to the Aprea Therapeutics, Inc. 2019 Equity Incentive Plan, and any amendment or amendments thereto, and each of the undersigned does hereby ratify and confirm all that each attorney and agent, or his or her substitutes, shall do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Oren Gilad | President, Chief Executive Officer and Director | March 16, 2026 |
| Oren Gilad, Ph.D. | (Principal Executive Officer) |  |
| /s/ John P. Hamill | Senior Vice President, Chief Financial Officer | March 16, 2026 |
| John P. Hamill | (Principal Financial and Accounting Officer) |  |
| /s/ Marc Duey | Director | March 16, 2026 |
| Marc Duey |  |  |
| /s/ Michael Grissinger | Director | March 16, 2026 |
| Michael Grissinger |  |  |
| /s/ John B. Henneman | Director | March 16, 2026 |
| John B. Henneman III |  |  |
| /s/ Rifat Pamukcu | Director | March 16, 2026 |
| Rifat Pamukcu, M.D. |  |  |
| /s/ Richard Peters | Director | March 16, 2026 |
| Richard Peters, M.D., Ph.D. |  |  |
| /s/ Gabriel Gruia | Director | March 16, 2026 |
| Gabriel Gruia, M.D. |  |  |
| /s/ Bernd Seizinger | Director | March 16, 2026 |
| Bernd R. Seizinger, M.D., Ph.D. |  |  |
| /s/ Jean-Pierre Bizzari | Director | March 16, 2026 |
| Jean-Pierre Bizzari, M.D. |  |  |

---

## Exhibit 5.1

**Exhibit 5.1**

---

| | |
|:---|:---|
| ![](tm268514d1_ex5-1img01.jpg) | DLA Piper LLP (US)<br> One Liberty Place<br> 1650 Market Street, Suite 5000<br> Philadelphia, PA 19103-7300<br> www.dlapiper.com |

---

March 16, 2026

Aprea Therapeutics, Inc.

3805 Old Easton Road

Doylestown, PA 18902

RE: <u>Aprea Therapeutics, Inc. - Registration Statement on Form S-8</u>

Ladies and Gentlemen:

We have acted as counsel to Aprea Therapeutics, Inc., a Delaware corporation (the "***Company***"), in connection with the filing by the Company of a Registration Statement on Form S-8 (the "***Registration Statement***") with the Securities and Exchange Commission (the "***Commission***") covering the offering of up to 327,701 shares (the "***Plan Shares***") of the Registrant's common stock, par value $0.001 per share (the "***Common Stock***") that may be issued pursuant to equity awards granted pursuant to the Aprea Therapeutics, Inc. 2019 Equity Incentive Plan (the "***Plan***").

In connection with this opinion, we have examined and relied upon (a) the Registration Statement and related prospectus, (b) the Company's certificate of incorporation and bylaws, each as currently in effect, and (c) such other records, documents, opinions, certificates, memoranda and instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. We have assumed the genuineness of all signatures (including, without limitation, all signatures via DocuSign, eSignature or similar technology), the authenticity and completeness of all documents submitted to us as originals, the conformity to originals of all documents submitted to us as certified or photostatic copies or telecopies or portable document file ("*PDF*") copies (and the authenticity of the originals of such copies), the accuracy, completeness and authenticity of certificates of public officials, and the due authorization, execution and delivery of all documents by all persons other than the Company where authorization, execution and delivery are prerequisites to the effectiveness thereof. As to certain factual matters, we have relied upon a certificate of an officer of the Company, which we assume to be accurate and complete, and have not independently verified such matters.

Our opinion is expressed only with respect to the General Corporation Law of the State of Delaware (without regard for decisional law). We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation.

On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Plan Shares have been duly authorized and, when and to the extent issued in accordance with the terms of the Plan and any award agreement entered into under the Plan, the Plan Shares will be validly issued, fully paid and nonassessable.

This opinion is limited to the matters expressly set forth in this letter, and no opinion has been or should be implied, or may be inferred, beyond the matters expressly stated. This opinion speaks only as to law and facts in effect or existing as of the date hereof and we disclaim any undertaking to advise you hereafter of any facts, circumstances, events or developments hereafter occurring or coming to our attention which may alter, affect or modify the opinions expressed herein.

We consent to the filing of this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act of 1933, as amended, or the rules and regulations of the Commission thereunder.

---

| |
|:---|
| Very truly yours, |
| /s/ DLA Piper LLP (US) |

---

## Exhibit 23.1

**Exhibit 23.1**

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We consent to the incorporation by reference in this Registration Statement of Aprea Therapeutics, Inc. on Form S-8 to be filed on or about March 16, 2026 of our report dated March 16, 2026, on our audits of the financial statements as of December 31, 2025 and 2024 and for each of the years then ended, which report was included in the Annual Report on Form 10-K filed March 16, 2026. Our report includes an explanatory paragraph about the existence of substantial doubt concerning the Company's ability to continue as a going concern.

/s/ EisnerAmper LLP

EISNERAMPER LLP

Philadelphia, Pennsylvania

March 16, 2026

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Aprea Therapeutics, Inc.**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Type**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Class Title**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Calculation Rule**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount Registered**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Proposed Maximum Offering Price Per Unit**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Maximum Aggregate Offering Price**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Rate**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount of Registration Fee**  |
| 1 | Equity | Common Stock, par value $0.001 | Other | 327701 | $0.85095 | $278857.17 | 0.0001381 | $38.51 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $278857.17  |  | $38.51  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $38.51  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Offering Note** <br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1</sup> (1a) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement on Form S-8 shall cover any additional shares of common stock, $0.001 par value per share ("Common Stock") of the Registrant that become issuable under the Aprea Therapeutics, Inc. 2019 Equity Incentive Plan (the "2019 Plan") by reason of any stock dividend, stock split, recapitalization, or other similar transaction effected without the Registrant's receipt of consideration which results in an increase in the number of the outstanding shares of Common Stock. (1b) Consists of shares of Common Stock under the 2019 Plan. (1c) Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act of 1933, as amended, and based upon the average of the high and low prices of the Registrant's Common Stock as reported on the Nasdaq on March 10, 2026.

---

| | |
|:---|:---|
| | |
| **Rule 457(p)** | **Rule 457(p)** |
| Fee Offset Claims | N/A |
| Fee Offset Sources | N/A |

---